Abstract: A culture composition for expanding a TIL, containing IL-2, IL-7, IL-15, and an immune checkpoint antibody or an antigen-binding fragment thereof. The immune checkpoint antibody comprises any one or more of a PD-1 antibody, a CTLA-4 antibody, a LAG-3 antibody, a TIM-3 antibody, a TIGIT antibody, and a BTLA antibody. The present invention further relates to a TIL expanding culture medium, a method for preparing a TIL population, and a pharmaceutical composition. In the culture composition, cell proliferation and activity are ensured while greatly reducing the used amount of IL-2, and IL-2 treatment is removed after infusing the TILs obtained using the culture composition into a patient so as to reduce side effects; moreover, no feeder cells are used in an expansion process, exogenous pollution is reduced and the manufacturing process is simplified, the manufacturing costs reduced, and the manufacturing time shortened.

Abstract: Provided is a nucleic acid construct, including the following elements: a transposon 3? terminal repeat, first poly A sequence, an insulator sequence having a transcription termination function, a transposon 5? terminal repeat, a transposase coding sequence, and a promoter that controls the expression of the transposase. Also provided are a host cell or pharmaceutical composition including said nucleic acid construct, and a use thereof.